GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.6800
-0.0420 (-5.82%)
Jan 29, 2026, 4:00 PM EST - Market closed
GT Biopharma Employees
GT Biopharma had 1 employees as of December 31, 2024. The number of employees decreased by 1 or -50.00% compared to the previous year.
Employees
1
Change (1Y)
-1
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$9,327,000
Market Cap
7.23M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 1 | -1 | -50.00% | 1 | 0 |
| Dec 31, 2023 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2022 | 2 | -6 | -75.00% | 2 | 0 |
| Dec 31, 2021 | 8 | 5 | 166.67% | 8 | 0 |
| Dec 31, 2020 | 3 | 1 | 50.00% | 3 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aptevo Therapeutics | 37 |
| Calidi Biotherapeutics | 28 |
| Theriva Biologics | 22 |
| Kiora Pharmaceuticals | 12 |
| Processa Pharmaceuticals | 10 |
| MetaVia | 9 |
| Alzamend Neuro | 7 |
| Immuron | 7 |
GTBP News
- 14 days ago - GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers - GlobeNewsWire
- 14 days ago - EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment - Benzinga
- 5 weeks ago - Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 - PRNewsWire
- 2 months ago - GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials - Accesswire
- 2 months ago - GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - GT Biopharma Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 6 months ago - GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2 - GlobeNewsWire
- 8 months ago - GT Biopharma Appoints New Member to its Board of Directors - GlobeNewsWire